Differential responses by neurotensin systems in extrapyramidal and limbic structures to ibogaine and cocaine

Brain Research

Volumn 818, Issue 1, 1999, Pages 96-104

  Alburges, Mario E ^a   Hanson, Glen R ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Cocaine; Dopamine; Drug abuse; Ibogaine; Methamphetamine; Neurotensin

Indexed keywords

AMPHETAMINE; COCAINE; DOPAMINE RECEPTOR BLOCKING AGENT; IBOGAINE; NEUROTENSIN;

ANIMAL TISSUE; ARTICLE; COCAINE DEPENDENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG DEPENDENCE; DRUG EFFECT; EXTRAPYRAMIDAL SYSTEM; FRONTAL CORTEX; IMMUNOREACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LIMBIC SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANIMALS; COCAINE; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRAPYRAMIDAL TRACTS; IBOGAINE; LIMBIC SYSTEM; MALE; NEUROTENSIN; PSYCHOTROPIC DRUGS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0033528288     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)01206-2     Document Type: Article

References (59)

1. Badio B., William L., Daly J.W. Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors. Mol. Pharmacol. 51:1997;1-5.
2. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
3. 3H] GBR-12935 binding to dopamine transporter protein NIDA Res. Monogr. 119:1992;285.
4. Broderick P.A., Phelan F.T., Eng F., Wechsler R.T. Ibogaine modulates cocaine responses which are altered due to environmental habituation: in vivo microvoltammetric and behavioral studies. Pharmacol. Biochem. Behav. 49:1994;711-728.
5. Cappendijk S.L., Dzoljic M.R. Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur. J. Pharmacol. 214:1993;261-265.
6. Chen K., Kokate T.G., Donevan S.D., Carroll F.I., Rogawski M.A. Ibogaine block of the NMDA receptor: in vitro and in vivo studies. Neuropharmacology. 35:1996;423-431.
7. Deecher D.C., Teitler M., Soderlund D.M., Bornmann W.G., Kuehne M.E., Glick S.D. Mechanisms of action of ibogaine and harmaline congeners based radioligand binding studies. Brain Res. 571:1992;242-247.
8. Dworkin S.I., Smith J.E. Neurobehavioral pharmacology of cocaine. NIDA Res. Monogr. 88:1988;185-198.
9. Ervin G.N., Birkemo L.S., Nemeroff C.B., Prange A.J. Neurotensin blocks certain amphetamine-induced behaviors. Nature. 291:1981;73-76.
10. Frey P., Fuxe K., Eneroth P., Agnati L. Effects of acute and long-term treatment with neuroleptics on regional telencephalic neurotensin levels in the male rat. Neurochem. Int. 8:1986;429-435.
11. Gershon S., Lang W.J. A psycho-pharmacological study of some indoles alkaloids. Arch. Int. Pharmacodyn. 135:1962;31-56.
12. Goeders N.E., Smith J.E. Cortical dopaminergic involvement in cocaine reinforcement. Science. 221:1983;773-775.
13. Govoni S., Hong J.S., Yang H.-Y.T., Costa E. Increase of neurotensin content elicited by neuroleptic in nucleus accumbens. J. Pharmacol. Exp. Ther. 215:1980;413-417.
14. Gygi S.P., Gibb J.W., Hanson G.R. Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions. J. Pharmacol. Exp. Ther. 270:1994;192-197.
15. Hanson G.R., Smiley P., Johnson M., Letter A., Bush L., Gibb J.W. Response by the neurotensin systems of the basal ganglia to cocaine treatment. Eur. J. Pharmacol. 160:1989;23-30.
16. G.R. Hanson, N. Singh, K. Merchant, M. Johnson, L. Bush, J.W. Gibb, Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse: involvement of dopaminergic mechanisms, in: P. Kitabgi, C.B. Nemeroff (Eds.), The Neurobiology of Neurotensin, New York Acad. Sci., Vol. 668, New York, 1992, pp. 165-172.
17. Hanson G.R., Singh N., Merchant K., Johnson M., Gibb J.W. The role of NMDA receptor systems in neuropeptide responses to stimulants of abuse. Drug Alcohol Depend. 37:1995;107-110.
18. Harsing L.G., Sershen H., Lajtha A. Evidence that ibogaine releases dopamine from the cytoplasmic pool in isolated mouse striatum. J. Neural Transm. 96:1994;215-225.
19. Jennes L., Stumpf W.E., Kalivas P.W. Neurotensin topographical distribution in rat brain by immunohistochemistry. J. Comp. Neurol. 210:1982;211-224.
20. Johnson C.E., Fischman M.W. The pharmacology of cocaine related to its abuse. Pharmacol. Rev. 41:1989;3-52.
21. Kesner R.P., Jackson-Smith P., Henry C., Amann K. Effects of ibogaine on sensory-motor function, activity, and spatial learning in rats. Pharmacol. Biochem. Behav. 51:1995;103-109.
22. Kobayashi R.M., Brown M., Vale W. Regional distribution of neurotensin and somatostatin in rat brain. Brain Res. 126:1977;584-588.
23. Letter A.A., Matsuda L.A., Merchant K.M., Gibb J.W., Hanson G.R. Characterization of dopaminergic influence on striatal-nigral neurotensin systems. Brain Res. 422:1987;200-203.
24. Letter A.A., Merchant K., Gibb J.W., Hanson G.R. Effect of methamphetamine on neurotensin concentrations in rat brain regions. J. Pharmacol. Exp. Ther. 241:1987;443-447.
25. H.S. Lotsof, Rapid method for interrupting the narcotic addiction syndrome, U.S. patent 4,499,096, 1985.
26. H.S. Lotsof, Rapid method for interrupting the cocaine and amphetamine abuse syndrome, U.S. patent 4,587,243, 1986.
27. H.S. Lotsof, Rapid method for attenuating the alcohol dependency syndrome, U.S. patent 4,857,523, 1989.
28. Lotsof H.S. Ibogaine in the treatment of chemical dependency disorders: clinical perspectives. Multidisciplinary Association for Psychedelic Studies. 5:1995;16-27.
29. Maisonneuve I.M., Keller R.W. Jr., Glick S.D. Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study. Eur. J. Pharmacol. 199:1991;35-42.
30. Maisonneuve I.M., Glick S.D. Interactions between ibogaine and cocaine in rats: in vivo microdialysis and motor behavior. Eur. J. Pharmacol. 212:1992;263-266.
31. Maisonneuve I.M., Keller R.W. Jr., Glick S.D. Interactions of ibogaine and D-amphetamine: in vivo microdialysis and motor behavior in rats. Brain Res. 579:1992;87-92.
32. Maisonneuve I.M., Mann G.L. C.R., Deibel C.R., Glick S.D. Ibogaine and the dopaminergic response to nicotine. Psychopharmacology. 129:1997;249-256.
33. Maidment N.T., Siddall B.J., Rudolph V.R., Erdelyi E., Evans C.J. Dual determination of extracellular cholecystokinin and neurotensin fragments in rat forebrain: microdialysis combined with a sequential multiple antigen radioimmunoassay. Neuroscience. 45:1991;81-93.
34. Mash D.C., Staley J.K., Baumann M.H., Rothman R.B., Hearn W.L. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci. 57:1995;45-50.
35. Mash D.C., Staley J.K., Pablo J.P., Holohean A.M., Hackman J.C., Davidoff R.A. Properties of ibogaine and its principal metabolite (12-hydroxyibogaine) at the MK-801 binding site of the NMDA receptor complex. Neurosci. Lett. 192:1995;53-56.
36. Merchant K.M., Letter A.A., Johnson M., Stone D.M., Gibb J.W., Hanson G.R. Effects of amphetamine analogs on neurotensin concentrations in rat brain. Eur. J. Pharmacol. 138:1987;151-154.
37. Merchant K.M., Letter A.A., Gibb J.W., Hanson G.R. Changes in the limbic neurotensin systems induced by dopaminergic drugs. Eur. J. Pharmacol. 153:1988;1-9.
38. Nemeroff C.B., Luttinger D., Hernandez D.E., Mailman R.B., Mason G.A., Davis S.D., Widerlov E., Frye F.G.D., Kilts C.D., Beaumont K., Breese G.R., Prange A.J. Jr. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. J. Pharmacol. Exp. Ther. 225:1983;337-345.
39. Palumbo P.A., Winter J.C. Stimulus effects of ibogaine in rats trained with yohimbine, DOM, or LSD. Pharmacol. Biochem. Behav. 43:1992;1221-1226.
40. Pearl S.M., Hough L.B., Boyd D.L., Glick S.D. Sex differences in ibogaine antagonism of morphine-induced locomotor activity and ibogaine brain levels and metabolism. Pharmacol. Biochem. Behav. 57:1997;809-815.
41. 3H] MK-801 binding to the NMDA receptor complex Psychopharmacology. 114:1994;672-674.
42. Popik P., Layer R.T., Skolnick P. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol. Rev. 47:1995;235-253.
43. Reid M.S., Hsu K. Jr., Souza K.H., Broderick P.A., Berger S.P. Neuropharmacological characterization of local ibogaine effects on dopamine release. J. Neural Transm. 103:1996;967-985.
44. Repke D.B., Artis D.R., Nelson J.T. Abbreviated ibogaine congeners. Synthesis and reactions of tropan-3-yl-2-and-3-indoles. Investigation of an unusual isomerization of 2-substituted indoles using computational and spectroscopic techniques. J. Org. Chem. 59:1994;2164.
45. Roberts D.C.S., Koob G.F., Klonoff P., Fibiger H.C. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacol. Biochem. Behav. 12:1980;781-787.
46. Schechter M.D., Gordon T.L. Comparison of the behavioral effects of ibogaine from three sources: mediation of discriminative activity. Eur. J. Pharmacol. 249:1993;79-84.
47. Schneider A.S., Nagel J.E., Mah S.J. Ibogaine selectively inhibits nicotine receptor-mediated catecholamine release. Eur. J. Pharmacol. 317:1996;R1-R2.
48. Sershen H., Hashim A., Harsing L.G. Jr., Lajtha A. Ibogaine antagonizes cocaine-induced locomotor stimulation in mice. Life Sci. 50:1992;1079-1086.
49. Sershen H., Hashim A., Lajtha A. Effect of ibogaine on serotonergic and dopaminergic interactions in striatum from mice and rats. Neurochem. Res. 19:1994;1463-1466.
50. Sershen H., Hashim A., Lajtha A. Ibogaine reduces preference for cocaine consumption in C57BL/6By mice. Pharmacol. Biochem. Behav. 47:1994;13-19.
51. 3-induced changes in stimulation-evoked dopamine release in vitro from striatum of C57BL/6By mice. Brain Res. Bull. 36:1995;587-591.
52. 3H] Serotonin from mouse striatum Pharmacol. Biochem. Behav. 53:1996;863-869.
53. 3H] Dopamine Brain Res. Bull. 40:1996;63-67.
54. Sershem H., Hashim A., Lajtha A. Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors. Brain Res. Bull. 42:1997;161-168.
55. Sheppard S.G. A preliminary investigation of ibogaine: case reports and recommendations for further study. J. Subst. Abuse Treat. 11:1994;379-385.
56. Sisko B. Interrupting drug dependency with ibogaine: a summary of four case histories. Multidisciplinary Association for Psychedelic Studies. 4:1993;15-24.
57. Uhl G.R., Snyder S.H. Regional and subcellular distribution of brain neurotensin. Life Sci. 19:1976;1827-1832.
58. Wagstaff J.D., Bush L.G., Gibb J.W., Hanson G.R. Endogenous neurotensin antagonizes methamphetamine-enhanced dopaminergic activity. Brain Res. 665:1994;237-244.
59. Wagstaff J.D., Gibb J.W., Hanson G.R. Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in striatum and nucleus accumbens. J. Pharmacol. Exp. Ther. 278:1996;547-554.